ClinicalTrials.gg

Colitis, Ulcerative clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,856 studies for Colitis, Ulcerative across more than 10 countries. 473 are recruiting or about to start. 1,252 of them are mainly about Colitis, Ulcerative (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 1,926 studies for Colitis, Ulcerative. How that becomes 1,854 here

This page counts the studies the registry files under Colitis, Ulcerative, and those it files under no condition that list Colitis, Ulcerativethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 1,926Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −15List Colitis, Ulcerative as a condition, but the registry did not file them under itMost often written as “Pediatric Ulcerative Colitis” (4), “Ulcerative Colitis Chronic Moderate” (3), and “Ulcerative Colitis Chronic Mild” (2). The registry filed them under other conditions only, most often Pediatric ulcerative colitis (6) and Inflammatory Bowel Diseases (5).
  3. −57Match it another way47 name it in the title, 3 in a keyword, and 7 by a synonym or other text the search reads.
  4. 1,854The count on this page55 of them list Colitis, Ulcerative in their own words; the registry filed them under no condition.

Status

Completed
847
Recruiting
306
Status unknown
186
Terminated
182
Not yet recruiting
135
Active, not recruiting
103

Phase

Phase 2
361
Phase 3
233
Phase 1
194
Phase 4
131
Early Phase 1
19

Where

United States
615
Canada
265
Germany
243
France
239
Poland
221
United Kingdom
215

Who develops what

Add Colitis, Ulcerative to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 65 programs from 48 companies, 55 with this as their studies’ main aim; 13 with a live phase 3 study; 19 primary completions in the next 12 months. Compare AbbVie, Eli Lilly and Johnson & Johnson here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
vedolizumabRecent, repeated
Evidence
  • NCT06850727 · Odyssey Therapeutics · Phase 2 · live · background · “Vedolizumab” · registered Feb 2025
  • NCT06570772 · Alvotech Swiss AG · Phase 3 · comparator · “Vedolizumab” · registered Aug 2024
  • NCT04469062 · Eli Lilly and Company · Phase 3 · comparator · “Vedolizumab IV” · registered Jul 2020
  • NCT03558152 · Hoffmann-La Roche · Phase 2 · comparator · “Vedolizumab” · registered Jun 2018
Takeda98% of its industry studiesUS: Takeda (FDA 2014)EU: Takeda (EMA 2014)22 studies
VancomycinRecent, repeated
Evidence
  • NCT07913347 · Metagen Therapeutics, Inc. · Phase 2 · live · background · “Vancomycin hydrochloride” · registered Oct 2026
  • NCT05370885 · vedanta biosciences inc · Phase 2 · background · “Vancomycin Oral Capsule” · registered Mar 2022
Pfizer27% of its industry studiesUS: off-patent, 32 generics marketed22 studies

3 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
afimkibart☆ Track4 live phase-3 studies: NCT07158242, NCT07846683, NCT06588855Hoffmann-La Roche
guselkumabApproved: US 2017 · EU 2017☆ Track4 live phase-3 studies: NCT05528510, NCT04033445, NCT06260163Johnson & Johnson
risankizumabApproved: US 2019 · EU 2019☆ Track3 live phase-3 studies: NCT07071519, NCT06880744, NCT03398135AbbVie
vedolizumabApproved: US 2014 · EU 2014☆ Track1 live phase-3 study: NCT06880744AbbVie
icotrokinraApproved: US 2026☆ Track1 live phase-3 study: NCT07196748Johnson & Johnson

The 5 in phase 3 with the nearest primary completion, of 65 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (19)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.HRS-7085 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 main aimNCT07229950 A Phase 2 Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HRS-7085 Tablets in Patients With Inflammatory Bowel Disease — primary endpoint: Proportion of subjects experiencing at least one Adverse Event · 48 enrolled
  • 17 Dec 2026 est.brivekimig · Sanofi · Phase 2 main aimNCT06975722 A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis — primary endpoint: Proportion of participants who achieve clinical remission at the end of Week 16 by modified Mayo Score (mMS) · 105 enrolled
  • 30 Dec 2026 est.mufemilast · Ganzhou Hemay Pharmaceutical Co., Ltd · Phase 2 main aimNCT05486104 Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis — primary endpoint: clinical remission · 92 enrolled

16 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Colitis, Ulcerative studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 9 open · JAK inhibitors 9 open · Stimulants 3 open · Immune checkpoint inhibitors 2 open · Corticosteroids 1 open

Coming up

163studies finish main data collection within a year11 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 306 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger. 71 (23%) take children under 18. 7 (2%) are for women only and 1 (<1%) for men only; 41 (13%) take healthy volunteers.

Recruiting studies that take each age, of 306
AgeWomenMen
1052 (17%)51 (17%)
18286 (93%)281 (92%)
30276 (90%)270 (88%)
40273 (89%)268 (88%)
50273 (89%)267 (87%)
65256 (84%)252 (82%)
75226 (74%)222 (73%)
85149 (49%)145 (47%)

Across all 1,856 studies, recruiting or not: 43% stop at 75 or younger and 23% at 65; 19% take children; 1% are for women only and 1% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Colitis, Ulcerative studies take

Of 154 phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 28 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 113 mo8–28 · 84 studies12 mo6–18 · 58 studies—
Phase 228 mo22–43 · 154 studies27 mo21–35 · 110 studies43 mo28–62 · 44 studies
Phase 348 mo31–75 · 101 studies47 mo31–70 · 87 studies—
Phase 443 mo25–63 · 63 studies—56 mo33–66 · 48 studies
Interventional, no phase34 mo15–54 · 237 studies—34 mo16–56 · 226 studies
Observational47 mo29–90 · 271 studies44 mo28–72 · 83 studies51 mo30–119 · 188 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,856. Browse all 1,856 → or search them.